265 related articles for article (PubMed ID: 12468176)
21. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium.
Al Kushi A; Lim P; Aquino-Parsons C; Gilks CB
Mod Pathol; 2002 Apr; 15(4):365-71. PubMed ID: 11950909
[TBL] [Abstract][Full Text] [Related]
22. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma.
Zheng W; Yi X; Fadare O; Liang SX; Martel M; Schwartz PE; Jiang Z
Am J Surg Pathol; 2008 Feb; 32(2):304-15. PubMed ID: 18223334
[TBL] [Abstract][Full Text] [Related]
23. The survival outcome and patterns of failure in node positive endometrial cancer patients treated with surgery and adjuvant radiotherapy with curative intent.
Rajasooriyar C; Bernshaw D; Kondalsamy-Chennakesavan S; Mileshkin L; Narayan K
J Gynecol Oncol; 2014 Oct; 25(4):313-9. PubMed ID: 25142629
[TBL] [Abstract][Full Text] [Related]
24. Apoptosis and the expression of Bcl-2 and Bax in patients with endometrioid, clear cell, and serous carcinomas of the uterine endometrium.
Kokawa K; Shikone T; Otani T; Nishiyama R; Ishii Y; Yagi S; Yamoto M
Gynecol Oncol; 2001 May; 81(2):178-83. PubMed ID: 11330946
[TBL] [Abstract][Full Text] [Related]
25. Aberrant expression of hypoxia-inducible factor 1α, TWIST and E-cadherin is associated with aggressive tumor phenotypes in endometrioid endometrial carcinoma.
Feng Z; Gan H; Cai Z; Li N; Yang Z; Lu G; Chen J
Jpn J Clin Oncol; 2013 Apr; 43(4):396-403. PubMed ID: 23372184
[TBL] [Abstract][Full Text] [Related]
26. Minor serous and clear cell components adversely affect prognosis in ''mixed-type'' endometrial carcinomas: a clinicopathologic study of 36 stage-I cases.
Quddus MR; Sung CJ; Zhang C; Lawrence WD
Reprod Sci; 2010 Jul; 17(7):673-8. PubMed ID: 20393071
[TBL] [Abstract][Full Text] [Related]
27. Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium.
Creasman WT; Kohler MF; Odicino F; Maisonneuve P; Boyle P
Gynecol Oncol; 2004 Dec; 95(3):593-6. PubMed ID: 15581969
[TBL] [Abstract][Full Text] [Related]
28. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer.
Amant F; Cadron I; Fuso L; Berteloot P; de Jonge E; Jacomen G; Van Robaeys J; Neven P; Moerman P; Vergote I
Gynecol Oncol; 2005 Aug; 98(2):274-80. PubMed ID: 15972232
[TBL] [Abstract][Full Text] [Related]
29. Endometrial carcinomas: a review emphasizing overlapping and distinctive morphological and immunohistochemical features.
Bartosch C; Manuel Lopes J; Oliva E
Adv Anat Pathol; 2011 Nov; 18(6):415-37. PubMed ID: 21993268
[TBL] [Abstract][Full Text] [Related]
30. The ARID1A, p53 and ß-Catenin statuses are strong prognosticators in clear cell and endometrioid carcinoma of the ovary and the endometrium.
Heckl M; Schmoeckel E; Hertlein L; Rottmann M; Jeschke U; Mayr D
PLoS One; 2018; 13(2):e0192881. PubMed ID: 29451900
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of E-cadherin protein expression in pathological stage I-III endometrial cancer.
Mell LK; Meyer JJ; Tretiakova M; Khramtsov A; Gong C; Yamada SD; Montag AG; Mundt AJ
Clin Cancer Res; 2004 Aug; 10(16):5546-53. PubMed ID: 15328195
[TBL] [Abstract][Full Text] [Related]
32. Local immune response in serous papillary carcinoma of the endometrium.
Tamiolakis D; Venizelos J; Lambropoulou M; Nikolaidou S; Tsikouras P; Jivannakis T; Papadopoulos N
Histol Histopathol; 2005 Apr; 20(2):403-8. PubMed ID: 15736043
[TBL] [Abstract][Full Text] [Related]
33. Serous versus high-grade endometrioid endometrial carcinoma: immunohistochemistry of RFP is not useful for differentiation.
Ussakli C; Usubutun A; Dincer N; Dolgun A; Bülbül D; Isikdogan Z; Haberal N; Ozen O; Tezel GG
Pol J Pathol; 2016; 67(3):221-227. PubMed ID: 28155970
[TBL] [Abstract][Full Text] [Related]
34. Claudin-3 and claudin-4 expression in serous papillary, clear-cell, and endometrioid endometrial cancer.
Konecny GE; Agarwal R; Keeney GA; Winterhoff B; Jones MB; Mariani A; Riehle D; Neuper C; Dowdy SC; Wang HJ; Morin PJ; Podratz KC
Gynecol Oncol; 2008 May; 109(2):263-9. PubMed ID: 18313739
[TBL] [Abstract][Full Text] [Related]
35. Expression of Glut-1 in Normal Endometrium and Endometrial Lesions: Analysis of 336 Cases.
Němejcová K; Rosmusová J; Bártů M; Důra M; Tichá I; Dundr P
Int J Surg Pathol; 2017 Aug; 25(5):389-396. PubMed ID: 28381136
[TBL] [Abstract][Full Text] [Related]
36. Expression of matrix metalloproteinase-26 and tissue inhibitors of metalloproteinases TIMP-3 and -4 in benign endometrium and endometrial cancer.
Tunuguntla R; Ripley D; Sang QX; Chegini N
Gynecol Oncol; 2003 Jun; 89(3):453-9. PubMed ID: 12798711
[TBL] [Abstract][Full Text] [Related]
37. WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium.
Acs G; Pasha T; Zhang PJ
Int J Gynecol Pathol; 2004 Apr; 23(2):110-8. PubMed ID: 15084838
[TBL] [Abstract][Full Text] [Related]
38. Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy.
Murphy KT; Rotmensch J; Yamada SD; Mundt AJ
Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1272-6. PubMed ID: 12654437
[TBL] [Abstract][Full Text] [Related]
39. ZEB1 overexpression associated with E-cadherin and microRNA-200 downregulation is characteristic of undifferentiated endometrial carcinoma.
Romero-Pérez L; López-García MÁ; Díaz-Martín J; Biscuola M; Castilla MÁ; Tafe LJ; Garg K; Oliva E; Matias-Guiu X; Soslow RA; Palacios J
Mod Pathol; 2013 Nov; 26(11):1514-24. PubMed ID: 23743934
[TBL] [Abstract][Full Text] [Related]
40. Comparison of myometrial invasion and tumor free distance from uterine serosa in endometrial cancer.
Ozbilen O; Sakarya DK; Bezircioglu I; Kasap B; Yetimalar H; Yigit S
Asian Pac J Cancer Prev; 2015; 16(2):519-22. PubMed ID: 25684481
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]